摘要
目的:探讨依达拉奉联合疏血通注射液治疗老年急性脑梗塞的疗效和安全性。方法:将110例住院的急性脑梗死患者,随机分为两组,治疗组56例,对照纽54例;治疗组给予治疗脑梗死的基础方案上加用依达拉奉注射剂和疏血通注射液;分别在治疗前、治疗后7、14、21d评估其神经功能缺损程度(ESS)和日常生活能力(ADL)。结果:治疗组总有效率明显高于对照组(P<0.05)。依达拉奉联合疏血通治疗第14d、第21d神经功能缺损的改善优于对照组(P<0.05);治疗后21d神经功能缺损的改善优于治疗前(P<0.05)。ADL改善于治疗第14、21d均优于对照组(P<0.05)。依达拉奉联合疏血通治疗组4例出现皮疹,2例出现皮下瘀点,2例出现恶心,1例出现肝功能轻度损害,停药后自行恢复正常。无颅内出血和消化道出血。两组间不良反应差异无统计学意义。结论:依达拉奉和疏血通治疗老年急性脑梗死临床疗效显著,且安全性高。
Objective:The Efficacy and safety of Edaravone and Shuxuetong injection on elderly patients with acute cerebral infarction were Investigated.Methods:The 110 cases hospitalized with acute cerebral infarction were randomly divided into two groups, which had 56 cases in the treatment group,and which had 54 cases in the control group.The treatment group was given edaravone injection and Shuxuetong injection based on the use of conventional solutions.The degree of neurological deficit(ESS) and the activities of daily living(ADL) was assessed before treatment and 7,14,21 d after treatment,respectively.Results:The treatment group' efficiency was significantly higher the control group(P<0.05).The treatment group was better than the control group in the improvements of ESS in 14d, 21d after treatment(P<0.05).At 21d after treatment,the improvements of ESS was better than the no treatment.The treatment group was better than the control group in the improvements of ADL in the treatment of the first 14,21 d(P<0.05).Adverse reactions between the two groups was no significant difference(P>0.05).Conclusion:The efficacy of Edaravone and Shuxuetong injection on elderly patients with acute cerebral infarction was outstanding,and it was safety.
出处
《中国医药导刊》
2011年第9期1552-1553,共2页
Chinese Journal of Medicinal Guide
关键词
急性脑梗死
依达拉奉
疏血通
Acute cerebral infarction
Edaravone
Shuxuetong
